---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-051009"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:57:05.414648+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Kymera Therapeutics CBO Elaine Caughey to depart April 10, 2023

## Summary
- Chief Business Officer Elaine Caughey departing for personal family reasons.
- Departure effective as of April 10, 2023.
- No replacement or interim appointment announced.

## SEC filing metadata
- accession: 0001193125-23-051009
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523051009/0001193125-23-051009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523051009/d463391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-051009
- JSON: https://secwatch.observer/filing/0001193125-23-051009.json
- Plain text: https://secwatch.observer/filing/0001193125-23-051009.txt

## Key facts
- Executive change
  Elaine Caughey departed as Chief Business Officer at Kymera Therapeutics, Inc..
  - Action: departing
  - Role: Chief Business Officer
  source text: Elaine Caughey, its Chief Business Officer, will be departing the Company for personal family reasons effective as of April 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523051009/0001193125-23-051009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.